EC
CABA icon

EntryPoint Capital’s Cabaletta Bio CABA Stock Holding History

EntryPoint Capital’s Portfolio CABA Stock Details CABA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$158K Buy
+50,927
New +$167K 0.04% 719
2024
Q2 		– Sell
-8,641
Closed -$147K – 1446
2024
Q1 		$147K Buy
+8,641
New +$185K 0.13% 226

Other funds holding CABA

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Woodline Partners
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

EntryPoint Capital's CABA Position: Q2 2026 in Review

EntryPoint Capital opened a new position in Cabaletta Bio (CABA) in Q2 2026: 50,927 shares worth $158K. The stake represents 0.04% of the portfolio and ranks #719 among its holdings. This is a return to the name: EntryPoint Capital previously reported a position in CABA as recently as Q1 2024.

EntryPoint Capital first reported a position in CABA in Q1 2024 and has held it in 2 quarters since. 139 funds tracked by Wall St. Rank hold CABA as of Q2 2026.

  • EntryPoint Capital held 50,927 shares of Cabaletta Bio worth $158K as of Q2 2026.
  • Cabaletta Bio was a new EntryPoint Capital position in Q2 2026.
  • Cabaletta Bio made up 0.04% of EntryPoint Capital's portfolio in Q2 2026, its #719 holding.
  • EntryPoint Capital first reported a position in Cabaletta Bio in Q1 2024 and has held it in 2 quarters since.
  • 139 funds tracked by Wall St. Rank held Cabaletta Bio as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.